| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Tumor necrosis factor receptor superfamily member 4; MRC OX40; OX40 antigen; OX40L receptor; CD134; Tnfrsf4; Ox40; Txgp1l |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived human TrkC/NTRK3 recombinant protein (Position: C32-H486). |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-TrkC/NTRK3 Antibody Picoband® is an antibody for NTRK3 detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Human,Mouse,Rat. Commonly used in WB, IHC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: NTRK3 (TNF receptor superfamily member 4); UniProt: Q16288
- Antibody format: Rabbit, Polyclonal, Rabbit IgG
- Molecular weight: 130 kDa
- Applications: WB, IHC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-TrkC/NTRK3 Antibody Picoband® catalog # A02502-2.
Biological background
Biological context: Receptor for TNFSF4/OX40L/GP34. Is a costimulatory molecule implicated in long-term T-cell immunity (By similarity). .
Expression and localization notes: cellular localization: Membrane; Single-pass type I membrane protein..
Common research applications
- Western blotting (WB): Compare NTRK3 levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of NTRK3 in tissue sections, considering fixation and antigen retrieval effects.
- Flow cytometry: Quantify NTRK3-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Background: NTRK3(Neurotrophic Tyrosine Kinase Receptor Type 3), also known as TRKC, is a protein that in humans is encoded by the NTRK3 gene. By PCR analysis of a somatic cell hybrid panel and by fluorescence in situ hybridization with the cDNA clone, McGregor et al.(1994) mapped the NTRK3 gene to 15q24-q25. Lamballe et al.(1991) isolated and characterized TRKC, a member of the TRK family of tyrosine protein kinase genes. They found that TRKC is preferentially expressed in the brain; in situ hybridization studies showed transcripts in the hippocampus, cerebral cortex, and the granular cell layer of the cerebellum. By functional studies in HeLa cells, Muinos-Gimeno et al.(2009) demonstrated that 5 miRNAs regulate the truncated form of NTRK3.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Membrane; Single-pass type I membrane protein.
- Research category: Adaptive Immunity,Autoimmune,B Cells,Cytokines,Hematopoietic Progenitors,Immune System Diseases,Immunology,Innate Immunity,Lymphoid,Stem Cells,T Cells,T Lymphocytic Lineage,TNF Superfamily
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.